Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | DRD4 | P21917 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 13/20 | 0.60 |
| ▸ | MAOA | P21397 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
| ▸ | BACE1 | P56817 | 1/20 | 0.59 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 5/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL250595 | 0.87 | ACHE (0.59) | DRD2DRD4ACHEMAOAMAOB | |
| SCHEMBL250719 | 0.80 | ACHE (0.58) | DRD2DRD4ACHEMAOAMAOB | |
| SCHEMBL4737625 | 0.79 | DRD2 (0.61) | MEN1NPC1KMT2ADRD2DRD4 | |
| SCHEMBL420827 | 0.79 | DRD2 (0.61) | DRD2DRD4ACHEBCHE | |
| SCHEMBL252049 | 0.79 | NAMPT (0.56) | DRD2DRD4ACHEMAOAMAOB | |
| SCHEMBL250703 | 0.78 | ACHE (0.57) | DRD2DRD4ACHEMAOAMAOB | |
| SCHEMBL7594227 | 0.77 | ACHE (0.55) | MEN1KMT2AACHEMAOAMAOB | |
| SCHEMBL4737630 | 0.76 | MEN1 (0.51) | MEN1NPC1KMT2ADRD2DRD4 | |
| SCHEMBL9572505 | 0.75 | DRD2 (0.63) | DRD2DRD4ACHEMAOBHTR4 | |
| SCHEMBL18768425 | 0.75 | MEN1 (0.51) | MEN1NPC1KMT2ADRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | PFIZER, INC. | 2003-03-06 | — | — | US | claimed |
| US-20020052373-A1 | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease | ZORN STEVIN H (US) | 2002-05-02 | — | — | US | claimed |
| EP-1201268-A2 | Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | claimed |
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-11-26 | — | — | US | disclosed |
| US-10316054-B2 | Preparation and use of crystalline beta-D-nicotinamide riboside | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-06-11 | — | — | US | disclosed |
| WO-2018033639-A1 | LACTONE INTERMEDIATES OF NICOTINAMIDE RIBOSIDE AND NICOTINATE RIBOSIDE | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2018-02-22 | — | — | WO | disclosed |
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-07-06 | — | — | US | disclosed |
| EP-3152220-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-04-12 | — | — | EP | disclosed |
| EP-3149016-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015186114-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015186068-A1 | PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-12-10 | — | — | WO | disclosed |
| US-20020049210-A1 | Heteroaryl amines as novel acetylcholinesterase inhibitors | CHEN YUHPYNG L (US) | 2002-04-25 | — | — | US | disclosed |
| US-6358941-B1 | ADMINISTERING GALANTAMINE OR DERIVATIVE; SIDE EFFECT REDUCTION | Snorrason, Ernir (IS) | 2002-03-19 | — | — | US | disclosed |
| US-6303633-B1 | FOR THERAPY AND PROPHYLAXIS OF ALZHEIMER'S DISEASE | PFIZER INC | 2001-10-16 | — | — | US | disclosed |
| US-6124321-A | Heteroaryl amines as novel acetyl cholinesterase inhibitors | PFIZER INC (US) | 2000-09-26 | — | — | US | disclosed |
| US-5965574-A | Heteroaryl amines as novel acetylcholinesterase inhibitors | CHEN YUHPYNG LIANG (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0918523-A1 | TREATMENT OF ARTHRITIS DISORDERS, RHEUMATOID ARTHRITIS AND MANIFESTATIONS ASSOCIATED WITH RHEUMATOID DISORDERS | Snorrason, Ernir (IS) | 1999-06-02 | — | — | EP | disclosed |
| US-5574046-A | Heteroaryl amines as novel acetylcholinesterase inhibitors | PFIZER INC. (US) | 1996-11-12 | — | — | US | disclosed |
| EP-0606248-A1 | HETEROARYL AMINES AS NOVEL ACETYL CHOLINESTERASE INHIBITORS | Eisai Co., Ltd. (JP) | 1994-07-20 | — | — | EP | disclosed |
| WO-1993007140-A1 | HETEROARYL AMINES AS NOVEL ACETYL CHOLINESTERASE INHIBITORS | PFIZER INC. (US) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052373-A1 | Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease | ACHE, BCHE, CHRM4 | MEN1 3739/4885NPC1 714/4885KMT2A 2509/4885 |
| US-20170189433-A1 | NICOTINAMIDE RIBOSIDE ANALOGS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | NNT, CS, ME2 | MEN1 1467/4885NPC1 1041/4885KMT2A 2811/4885 |
| US-20030045449-A1 | Pharmaceutical combinations for the treatment of neurodegenerative diseases | GRIN3A, GRIN1, CHRNA10 | MEN1 3328/4885NPC1 1031/4885KMT2A 994/4885 |
| US-20020049210-A1 | Heteroaryl amines as novel acetylcholinesterase inhibitors | ACHE, BCHE, CHAT | MEN1 3891/4885NPC1 1310/4885KMT2A 353/4885 |
| US-10316054-B2 | Preparation and use of crystalline beta-D-nicotinamide riboside | NNT, HADHB, NAMPT | MEN1 2090/4885NPC1 367/4885KMT2A 4479/4885 |
| US-10485814-B2 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof | NNT, CS, ME2 | MEN1 1467/4885NPC1 1041/4885KMT2A 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.